Oncolytic Herpes Simplex Virus-Based Therapies for Cancer

被引：53

作者：

Aldrak, Norah ^{[1
]}

Alsaab, Sarah ^{[1
,2
]}

Algethami, Aliyah ^{[1
]}

Bhere, Deepak ^{[3
,4
,5
]}

Wakimoto, Hiroaki ^{[3
,4
,5
,6
]}

Shah, Khalid ^{[3
,4
,5
]}

Alomary, Mohammad N. ^{[1
,2
]}

Zaidan, Nada ^{[1
,2
]}

机构：

[1] King Abdulaziz City Sci & Technol, Ctr Excellence Biomed, Joint Ctr Excellence Program, POB 6086, Riyadh 11451, Saudi Arabia

[2] King Abdulaziz City Sci & Technol, Natl Biotechnol Ctr, Life Sci & Environm Res Inst, POB 6086, Riyadh 11451, Saudi Arabia

[3] Harvard Med Sch, Brigham & Womens Hosp, Ctr Stem Cell Therapeut & Imaging CSTI, Boston, MA 02115 USA

[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA

[5] Harvard Med Sch, Brigham & Womens Hosp, BWH Ctr Excellence Biomed, Boston, MA 02115 USA

[6] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA

来源：

CELLS | 2021年 / 10卷 / 06期

关键词：

oncolytic herpes simplex virus (oHSV); virotherapy; immunotherapy; cancer; MESENCHYMAL STEM-CELLS; TALIMOGENE LAHERPAREPVEC; ANTITUMOR-ACTIVITY; SYSTEMIC DELIVERY; CLINICAL-TRIALS; STROMAL CELLS; EFFICACY; MUTANT; REPLICATION; IMMUNITY;

D O I：

10.3390/cells10061541

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells while sparing normal cells. This leads to the direct killing of cancer cells and the activation of the host immunity to recognize and attack the tumor. Different variants of oHSV have been developed to optimize its antitumor effects. In this review, we discuss the development of oHSV, its antitumor mechanism of action and the clinical trials that have employed oHSV variants to treat different types of tumor.

引用

页数：17

共 106 条

[1] Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16 [J].

Aghi, M. ;

Visted, T. ;

DePinho, R. A. ;

Chiocca, E. A. .

ONCOGENE, 2008, 27 (30) :4249-4254

[2] Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma [J].

Andtbacka, Robert H. I. ;

Amatruda, Thomas ;

Nemunaitis, John ;

Zager, Jonathan S. ;

Walker, John ;

Chesney, Jason A. ;

Liu, Kate ;

Hsu, Cheng-Pang ;

Pickett, Cheryl A. ;

Mehnert, Janice M. .

EBIOMEDICINE, 2019, 47 :89-97

[3] Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma [J].

Andtbacka, Robert H., I ;

Collichio, Frances ;

Harrington, Kevin J. ;

Middleton, Mark R. ;

Downey, Gerald ;

Ohrling, Katarina ;

Kaufman, Howard L. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[4] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[5] Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial [J].

Andtbacka, Robert H. I. ;

Ross, Merrick ;

Puzanov, Igor ;

Milhem, Mohammed ;

Collichio, Frances ;

Delman, Keith A. ;

Amatruda, Thomas ;

Zager, Jonathan S. ;

Cranmer, Lee ;

Hsueh, Eddy ;

Chen, Lisa ;

Shilkrut, Mark ;

Kaufman, Howard L. .

ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (13) :4169-4177

[6] Viruses for Tumor Therapy [J].

Bell, John ;

McFadden, Grant .

CELL HOST & MICROBE, 2014, 15 (03) :260-265

[7] Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes [J].

Bellone, Matteo ;

Calcinotto, Arianna .

FRONTIERS IN ONCOLOGY, 2013, 3

[8] Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation [J].

Benencia, Fabian ;

Courreges, Maria C. ;

Fraser, Nigel W. ;

Coukos, George .

CANCER BIOLOGY & THERAPY, 2008, 7 (08) :1194-1205

[9] Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation [J].

Blank, SV ;

Rubin, SC ;

Coukos, G ;

Amin, KM ;

Albelda, SM ;

Molnar-Kimber, KL .

HUMAN GENE THERAPY, 2002, 13 (05) :627-639

[10] Integrating oncolytic viruses in combination cancer immunotherapy [J].

Bommareddy, Praveen K. ;

Shettigar, Megha ;

Kaufman, Howard L. .

NATURE REVIEWS IMMUNOLOGY, 2018, 18 (08) :498-513

← 1 2 3 4 5 6 7 8 9 10 →